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Abstract Three closely related human SEC14p-like
proteins (hTAP1, hTAP2, hTAP3, or SEC14L2, SEC14L3,
SEC14L4, respectively) have been described that are
related to the Saccharomyces cerevisiae SEC14 protein.
These proteins may participate in intracellular lipid trans-
port and influence regulatory lipid-dependent events. Here
we report the isolation of an alternatively spliced hTAP3
cDNA and a polymorphism within the coding region of the
hTAP3/SEC14L4 gene.
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Introduction
Three human tocopherol associated proteins (hTAP1, hTAP2,
hTAP3, also named SEC14L2, SEC14L3, SEC14L4,
respectively) have been described [1, 2]. Although the three
genes are closely related at the nucleic acid and protein
sequence (reviewed in [3–5]), they are expressed at different
levels in human tissue and exhibit cell specificity within the
same organ [1, 6, 7]. Among the tested human tissues, high
expression of hTAP3 was seen in the epithelial duct cells of
several glands [7]. To date no diseases directly linked to the
hTAP genes have been described. However, mutations in
related proteins such as PITP, a-TTP, CRALBP or ATCAY
can lead to hereditary disease, clearly underlying the
importance of a correct protein-mediated distribution of
hydrophobic molecules [8–12].
The hTAP proteins can recognize phospholipids, squa-
lene, and specific tocopherol analogues and derivatives,
suggesting that they may contribute to the cellular uptake,
intracellular distribution and secretion of several ligands [1,
13–15]. In addition, the hTAP proteins interact with
phosphatidylinositol kinase (PI3K) and possibly modulate
the PI3K/PKB signal transduction pathway [1]. This find-
ing was confirmed in prostate tumours in which over-
expression of TAP1 increased tocopherol uptake and acted
as tumour suppressor by modulating PI3K/PKB activity
and cell proliferation [16, 17]. Tocopherols and phospha-
tidylinositol compete for binding to hTAPs, suggesting that
tocopherols may modulate phospholipid-dependent sig-
nalling pathways [1, 14]. Since the hTAP proteins show a
selective binding capacity toward the different natural
tocopherols and tocotrienols [15], it can be assumed that
these proteins confer specificity by mediating their recog-
nition and selective transport to enzymes, transcription
factors, nuclear receptors, organelles such as mitochondria,
or specific plasma domains [7].
Here we describe an alternative spliced form of the
hTAP3/hSEC14L4 gene and a polymorphism in its coding
sequence. The possible role for these hTAP3 variants is
discussed.
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Materials and methods
As previously described, the tissue samples were from
transplant donors and had the quality of transplantable
material [18]. They were immediately frozen in liquid
nitrogen and kept at -80C if not immediately processed.
Total RNA was isolated from tissues using RNAeasy
extraction kit (Qiagen). Reverse transcription RT–PCR was
performed basically according to the RT–PCR kit from
Perkin-Elmer. For detecting the alternatively spliced version
of hTAP3 cDNA, a PCR product was obtained by using
primers: sense TAP3-Bf (50-CATGAGCAGCCGAGTC
GGG-30) and antisense TAP3-Br (50-CCATGTGACAAT
GTTGTCCAG-30). Conditions for PCR were: 95 for 20 s,
62 for 20 s, 72 for 20 s, for 35 cycles, using Hot Star
Polymerase. Screening for the 16 bp insertion included
reverse transcription followed by PCR amplification of a
short 223 bp fragment (239 bp with the insertion), purifi-
cation, gel extraction and cleavage by BamHI. Expected
sizes:
Normal PCR product : 223 bp
+ cut with BamHI
223 bp
PCR product þ 16 bp insert : 239 bp
+ cut with BamHI
175 bp þ 56 bp
For detecting the PstI polymorphism, a region potentially
containing the PstI site was amplified by using primer
hTAP3afw (50-CATGAGCAGCCGAGTCGGG-30) and
hTAP3arv (50-GGGCTCGAATAACAATTAAATT-30).
Conditions for PCR were as follows: 95C, 30 s; 55C, 30 s;
and 72C, 1 min, for 35 cycles. PCR products of 580 bp size
were purified by gel extraction and the presence of the PstI
restriction site determined by enzymatic cleavage with PstI.
Direct sequencing of hTAP3 clones was performed by
Microsynth (Balgach, Switzerland).
Results and discussion
During sequencing of the hTAP3 (or hSEC14L4) cDNA
[1], two mutations were detected: the insertion of a short
16 bp fragment at position ?55 (Fig. 1a), and a silent point
mutation at position ?409 of the coding sequence
(Fig. 1b). Both changes are leading to the formation of new
and unique restriction sites; the 16 bp insertion contained a
unique BamHI restriction site, whereas the silent point
mutation generated a unique PstI restriction site. This
allowed the application of a fast screening method con-
sisting of PCR-mediated amplification of a short region of
the hTAP3 cDNA, followed by restriction fragment length
analysis (see methods).
Because hTAP3 is not expressed in cell lines [7], total
RNA isolated from human tissues was used to screen for
the presence of the hTAP3 gene variants. The analysis
performed on different tissues from seven different donors
indicated that the majority of the samples express about
equal amounts of hTAP3 with and without the 16 bp
insertion derived from alternative splicing (Fig. 2;
Table 1). At this time, no firm statement can be made about
relative expression levels of the two alternatively spliced
forms, since cells in a tissue could either express both
forms in each cell, or one cell type in a tissue may express
one form and another cell type the other. However, donor 1
contains only the correctly spliced version of hTAP3 in
both liver and skin, possibly indicating that alternative
(A) hTAP3 cDNA sequence +1 - + 138 
ATGAGCAGCCGAGTCGGGGACCTGAGCCCCCAGCAGCAGGAAGCGCTGGCCAGG----------------
ATGAGCAGCCGAGTCGGGGACCTGAGCCCCCAGCAGCAGGAAGCGCTGGCCAGGATCCTCCTCCGCTCAG
            Bam HI
TTCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACTACTTCCTCCTGCGCTG
TTCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACTACTTCCTCCTGCGCTG
(B) hTAP3 cDNA sequence + 376 - + 444 
AAAGTCTGTGAGCTGCTGTTGCATGAGTGTGAGCTGCAAACTCAGAAGCTGGGCAGGAAGATCGAGATG
AAAGTCTGTGAGCTGCTGTTGCATGAGTGTGAGCTGCAGACTCAGAAGCTGGGCAGGAAGATCGAGATG
         PstI 
Fig. 1 Polymorphism and alternative splicing of the human
SEC14L4 gene. a Two versions of hTAP3 cDNA sequences detected
during amplification and cloning of hTAP3 cDNA. The insertion of
16 bp (grey shading) originated from the first intron at position ?55
by alternative splicing, generating a new, unique BamHI restriction
site (GGATCC, underlined). So far, a new protein product related to
this insertion was not identified, most likely because the insertion of
16 bp results in a shift of the open reading frame, generating
truncated proteins stopping at alternative stop codons unless an
alternative start codon is used. Start (ATG) and stop codons (TGA)
are indicated in bold. The sequence of the PCR fragment containing
the alternatively spliced hTAP3 mRNA has been submitted to
Genbank (accession number FJ824055). b Mutation in one base at
position ?414 (A ? G, bold) (or as reverse complement, C ? T)
generates a new restriction site (PstI, underlined) which is present
also in the hTAP2 cDNA. Mutation itself does not change the amino
acid (Gly ? Gly), but might be linked with other mutations. This
mutation corresponds to the C/T small nucleotide polymorphism
(dbSNP:9606738), which is described at http://www.ncbi.nlm.nih.
gov/SNP/snp_ref.cgi?type=rs&rs=9606738
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splicing occurs in a regulated manner, or as a consequence
of additional changes that influence it in a tissue and/or
individual specific manner. This may be the result of
alterations in the splicing consensus sequence or the
splicing machinery, although no polymorphisms have been
so far described within intron 1 (http://www.ncbi.nlm.nih.
gov/SNP/snp_ref.cgi?locusId=284904). Sequence analysis
of the exon–intron junction between exon 1 and 2 revealed
that the additional 16 bp in the alternatively spliced hTAP3
cDNA come from alternative usage of the 30-splicing
junction of intron 1 (Fig. 3a). Alignment of the three clo-
sely related hTAP sequences (hTAP1, hTAP2, hTAP3)
showed that the 30-splice junction of hTAP3 in intron 1 is
shifted by 4 nucleotides possibly allowing the usage of two
alternative splicing sites (Fig. 3b). Interspecies sequence
alignment of the intron 1–exon 2 junction of hTAP3
revealed that the alternative 30-splice junction is present in
humans, chimpanzee, and rhesus monkeys, but not in
mouse or rabbits, possibly indicating that alternative
splicing of hTAP3 evolved only in higher primates
(Fig. 3c).
The hTAP3 cDNAs from three of four tested donors
contain a PstI restriction site (Table 1). The PstI polymor-
phism (dbSNP:9606738) has been described to occur at
different frequency in different ethnic groups (Table 2)
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?type=rs&
rs=9606738). In the sequences so far analyzed, the C/C
genotype (PstI site present in both alleles) occurs mainly in
the European, the C/T genotype (PstI site present in one
allele) in the European and African, and the T/T genotype
(PstI site absent in both alleles) in the Asian population.
At this time it is not possible to estimate the importance
of the here described hTAP3 gene variants, because until
now research has mainly focused on hTAP1 and estab-
lishing a link with certain diseases requires a better
understanding of the three closely related hTAP proteins.
The three hTAP proteins may participate in intracellular
lipid transport and consequently influence lipid metabolism
as well as lipid-dependent events, including signal trans-
duction, gene expression and secretion.
We and others have found that hTAP proteins can mod-
ulate phosphatidylinositol-3-kinase (PI3K) in vitro [1, 16];
other enzymes such as phosphatidylinositol-4-kinase
(PI4K), phospholipases, squalene epoxidase, fatty acid
synthase, and choline-phosphate cytidyltransferases may be
modulated by hTAPs as well. A role for TAP proteins in the
biosynthesis of cholesterol was firstly suggested by the
identification of TAP1/SEC14L2 as the previously descri-
bed microsomal supernatant protein factor (SPF) [19]. SPF/
TAP1/SEC14L2 stimulates squalene epoxidation, a reaction
required for cholesterol synthesis, either by directly stimu-
lating squalene transport to the enzyme or possibly by
increasing the transport and generation of vesicles carrying
squalene [19, 20]. As shown with TAP1/SPF-knockout
mice, SPF/TAP1/SEC14L2 maintains the steady-state
plasma cholesterol level during fasting by compensating for
decreased squalene epoxidase and HMG-CoA reductase
activity [21].
Modulation of PI3K by hTAPs may also affect gene
expression in a tocopherol-dependent manner, e.g. by
affecting the PI3K/PKB/PPARc signal transduction path-
way. Indeed, the involvement of TAP1 in the modulation
of gene expression has been recently described; mouse
TAP1 was found to stimulate the expression of the mast
cell proteases genes mmcp-1 and mmcp-7, whereas the
expression of TAP1 itself can be up-regulated by activin/
TGF-b treatment during differentiation of bone-marrow
Liver 1  Liver 2       Lung 2  Lung 3        Skin 4   Skin 1 
M     -     +     -     +            -     +     -     +            -     +     -     +    BamHI  
200 bp - 
100 bp - 
-223/239 bp 
-175 bp 
-56 bp 
Fig. 2 Screening for the alternatively spliced human SEC14L4
mRNA. Screening was performed as described in methods. Two
aliquots of each sample—one cut with BamHI (?) and one uncut
(-)—were separated by a 2.5% agarose gel, visualized with ethidium
bromide, scanned and analysed using a Lumimager. Samples from
different individuals are labelled 1, 2, 3, and 4. In all samples two
variants of hTAP3 gene are detectable, with exception of donor 1,
where a BamHI cleaved alternatively spliced form was not observed
in liver and in skin
Table 1 Occurrence of alternative splicing of hTAP3 in different tissues of seven individuals as detected using the newly generated BamHI
restriction site
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Tissue
PstI polymorphism positive ? ? ? -
BamHI positive (alternative splicing present) ? ? Lung
- ? Liver
? ? ? Muscle
- ? Skin
- - Adrenal
? Placenta
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derived mast cells [22, 23]. The expression of hTAP1 is up-
regulated during primary mast cell differentiation, indi-
cating a role of this protein in cells of the native immune
system [7]. Expression of TAP2 is inversely correlated
with allergic airway inflammation [24].
hTAP1 and hTAP2 are expressed, although at a low
level, in several cell lines, whereas hTAP3 expression is
undetectable in so far all tested cell lines; interestingly, in
primary cells and tissues the three hTAP proteins appear to
be more abundant [7]. These results suggest that the hTAP
proteins may be expressed in the fully differentiated state
or interfere with proliferation, possibly becoming down-
regulated during cell line expansion and/or tumor promo-
tion [16, 25]. Accordingly, previous results suggested that
Table 2 Occurrence of PstI polymorphism in the population
Population ss# # Samples C/C C/T T/T C T
European ss23630390 48 0.083 0.250 0.667 0.208 0.792
African-American ss23630390 46 0.000 0.478 0.522 0.239 0.761
Asian ss23630390 48 0.000 0.000 1.000 0.000 1.000
European ss48402672 120 0.033 0.417 0.550 0.242 0.758
Asian ss48402672 90 0.000 0.067 0.933 0.033 0.967
Asian ss48402672 88 0.000 0.023 0.977 0.011 0.989
Sub-Saharan African ss48402672 120 0.000 0.133 0.867 0.067 0.933
Multiple ss48402672 56 0.036 0.143 0.821 0.107 0.893
(A) hTAP3 genomic sequence exon 1, intron 1 and part of exon 2 
hTAP3 ATGAGCAGCCGAGTCGGGGACCTGAGCCCCCAGCAGCAGGAAGCGCTGGCCAGGgtgagg
     ----------------------intron 1 (1740 bp)-------------------- 
     ggttggtggcccccgaggtcatgagagctccgccgaccatcagatcctcctccgctcagT
     TCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACTACTTCCTCC 
(B) Alignment of intron 1 - exon 2 junction of hTAP1, hTAP2 and hTAP3 
     
yTnAy <------- 21-34 bp --------> 
hTAP1  ccacgatgagcggcagagtcggcgatctgagccccaggcagaaggaggcattggccaagT
hTAP2  agtctggaggccaaggctcaatgtgagagagccactttaaccagcatctctcttgccagT
hTAP3      ggttggtggcccccgaggtcatgagagctccgccgaccatcagatcctcctccgctcagT
hTAP1  TTCGGGAGAATGTCCAGGATGTGCTGCCGGCCCTGCCGAATCCAGATGACT 
hTAP2  TCCGAGAAAACGTCCAGGATGTGCTTCCTGCCCTGCCCAACCCTGATGATT 
hTAP3  TCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACT 
(C) Interspecies alignment of intron 1 - exon 2 junction of TAP3 
hTAP3     ggttggtggcccccgaggtcatgagagctccgccgaccatcagatcctcctccgctcagT
ptTAP3    ggttggtggcccccgaggtcatgagagctccgccgaccatcagatcctcctccgctcagT
mmTAP3    ggttggtggcccccaaggtcatgagagttccgctgaccatcagctcttcccccgctcagT
mTAP3     ggctctgacccagatgaccaggaacactctgaccatcacacccatccttttcctcctagT
rTAP3     gactctgacccagatgaccaggaacactctgattaccgcatccatccttttcctcctagT
hTAP3  TCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACT 
ptTAP3 TCCGGGAGAACCTCCAGGACCTGCTGCCCATACTGCCCAATGCTGATGACT 
mmTAP3 TCCGGGAGAACCTCCAGAACCTGCTGCCCATGCTGCCCAATGCTGATGACT 
mTAP3  TCCGGGAGACCCTCCAGGATCTGCTGCCCACCCTGCCCAAGGCCGATGACT 
rTAP3  TCCGGGAGATCCTCCAGGATGTGCTGCCCACCCTGCCCAAGGCTGACGACT 
Fig. 3 Alternative splicing of hTAP3 intron 1. a Alternative usage of
the 30-splice junction of hTAP3. Shown is the genomic sequence
of exon 1, intron 1 and start of exon 2 of the hTAP3 gene. Start of
protein (ATG, bold), intronic 50- and 30-junctions (bold), inserted
sequence after alternative splicing (underlined). Exons (upper case),
intron (lower case). b Alignment of the intron 1—exon 2 junctions of
hTAP1, hTAP2, and hTAP3. The conserved dinucleotides ag of the
30-splice junctions are shown in bold, the nucleotides conserved in
two of the three genes in grey shading, the most likely splicing branch
point adenine in hTAP1 is marked by an arrow. Homologies to the
human branch point consensus sequence yTnAy are shown in bold
[34]. In hTAP3, the distance of the 30-splice junction to the branch
point is longer, possibly explaining the usage of an additional 30-
splice junction in hTAP3. Intron (lower case), exon (upper case).
c Alignment of the intron 1—exon 2 junctions of TAP3 from Homo
sapiens (hTAP3), Macaca mulatta (mmTAP3), Pan troglodytes
(ptTAP3), Mus musculus (mTAP3) and Rattus norvegicus (rTAP3).
Homologies to the human branch point consensus sequence yTnAy
are shown in bold [34]. The most likely branch point and alternative
splicing junction are conserved in primates, but not in rodents
3506 Mol Biol Rep (2010) 37:3503–3508
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epigenetic changes are at the basis of hTAP1 gene silencing
in cancer cells, since treatment with demethylating agents
can recover TAP expression [7, 16]. Moreover, over-
expression of hTAP1 in mesothelioma cells renders them
more sensitive to a-tocopheryl succinate, again suggesting
that hTAP down-regulation may serve to escape the apop-
totic effects of this anti-proliferative compound [26]. In line
with this, proliferation of prostate cancer cells correlates
with a reduced expression of hTAP1 [16, 17] whereas certain
small nucleotide polymorphisms (SNP) in the hTAP1 gene
are associated with an increased risk for prostate cancer
[27, 28]. Moreover, lower levels of hTAP1 have been
detected in breast cancer [25, 29].
hTAP3/SEC14L4 is predominantly expressed in epi-
thelial duct cells of several glands (e.g. salivary gland,
prostate, pancreas, mammary gland), suggesting that it may
be involved in polarized secretion from these cells [7].
Accordingly, the related Saccharomyes cerevisiae SEC14p
mediates vesicle formation and secretion from endosomes
and trans-Golgi network possibly through activation of
PI4K [30–32]. Alternatively, the hTAP function may have
shifted from lipid transfer to enzymes to lipid insertion into
secretory vesicles, organelles or specific plasma domains.
In conclusion, the here detected gene polymorphism
could be used as a chromosomal linkage marker, e.g. to
establish a correlation between ethnic differences seen in
incidences of diseases and specific hTAP3 gene variants.
The presence of the alternatively spliced form could lead to
reduced levels of functional hTAP3 protein expression
what may not necessarily lead to a disease, but may play a
role in determining inter-individual differences in the
secretory and/or proliferative capability of epithelial duct
cells [7], alter the risk for certain diseases and possibly
influence the disease-preventive effects of vitamin E in
supplementation studies [33].
A further analysis of the biological relevance of the here
described hTAP3 variants requires the definite assignment
of the wild type hTAP3 function. Future studies should
address the molecular role of these hTAP3 variants and
their pattern of expression in normal and pathological tis-
sues, possibly with single cell resolution to reveal cell type
specific splicing patterns.
Acknowledgments This work was supported by the Swiss National
Science Foundation.
References
1. Kempna P, Zingg JM, Ricciarelli R, Hierl M, Saxena S, Azzi A
(2003) Cloning of novel human SEC14p-like proteins: ligand binding
and functional properties. Free Radic Biol Med 34:1458–1472
2. Ye X, Ji C, Yin G, Tang R, Zeng L, Gu S, Ying K, Xie Y, Zhao
RC, Mao Y (2004) Characterization of a human Sec14-like
protein cDNA SEC14L3 highly homologous to human SPF/TAP.
Mol Biol Rep 31:59–63
3. Mousley CJ, Tyeryar KR, Vincent-Pope P, Bankaitis VA (2007)
The Sec14-superfamily and the regulatory interface between
phospholipid metabolism and membrane trafficking. Biochim
Biophys Acta 1771:727–736
4. Bankaitis VA, Vincent P, Merkulova M, Tyeryar K, Liu Y (2007)
Phosphatidylinositol transfer proteins and functional specification
of lipid signaling pools. Adv Enzyme Regul 47:27–40
5. Saito K, Tautz L, Mustelin T (2007) The lipid-binding SEC14
domain. Biochim Biophys Acta 1771:719–726
6. Zimmer S, Stocker A, Sarbolouki MN, Spycher SE, Sassoon J,
Azzi A (2000) A novel human tocopherol-associated protein:
cloning, in vitro expression, and characterization. J Biol Chem
275:25672–25680
7. Zingg JM, Kempna P, Paris M, Reiter E, Villacorta L, Cipollone
R, Munteanu A, De Pascale C, Menini S, Cueff A, Arock M, Azzi
A, Ricciarelli R (2008) Characterization of three human sec14p-
like proteins: alpha-tocopherol transport activity and expression
pattern in tissues. Biochimie 90(11–12):1703–1715
8. Milligan SC, Alb JG, Elagina RB, Bankaitis VA, Hyde DR
(1997) The phosphatidylinositol transfer protein domain of Dro-
sophila retinal degeneration B protein is essential for photore-
ceptor cell survival and recovery from light stimulation. J Cell
Biol 139:351–363
9. Hamilton BA, Smith DJ, Mueller KL, Kerrebrock AW, Bronson
RT, van Berkel V, Daly MJ, Kruglyak L, Reeve MP, Nemhauser
JL, Hawkins TL, Rubin EM, Lander ES (1997) The vibrator
mutation causes neurodegeneration via reduced expression of
PITP alpha: positional complementation cloning and extragenic
suppression. Neuron 18:711–722
10. Maw MA, Kennedy B, Knight A, Bridges R, Roth KE, Mani EJ,
Mukkadan JK, Nancarrow D, Crabb JW, Denton MJ (1997) Mutation
of the gene encoding cellular retinaldehyde-binding protein in auto-
somal recessive retinitis pigmentosa. Nat Genet 17:198–200
11. Yokota T, Uchihara T, Kumagai J, Shiojiri T, Pang JJ, Arita M,
Arai H, Hayashi M, Kiyosawa M, Okeda R, Mizusawa H (2000)
Postmortem study of ataxia with retinitis pigmentosa by mutation
of the alpha-tocopherol transfer protein gene. J Neurol Neurosurg
Psychiatry 68:521–525
12. Bomar JM, Benke PJ, Slattery EL, Puttagunta R, Taylor LP,
Seong E, Nystuen A, Chen W, Albin RL, Patel PD, Kittles RA,
Sheffield VC, Burmeister M (2003) Mutations in a novel gene
encoding a CRAL-TRIO domain cause human Cayman ataxia
and ataxia/dystonia in the jittery mouse. Nat Genet 35:264–269
13. Kempna P, Cipollone R, Villacorta L, Ricciarelli R, Zingg JM (2003)
Isoelectric point mobility shift assay for rapid screening of charged
and uncharged ligands bound to proteins. IUBMB Life 55:103–107
14. Habermehl D, Kempna P, Azzi A, Zingg JM (2005) Recombinant
SEC14-like proteins (TAP) possess GTPase activity. Biochem
Biophys Res Commun 326:254–259
15. Panagabko C, Morley S, Hernandez M, Cassolato P, Gordon H,
Parsons R, Manor D, Atkinson J (2003) Ligand specificity in the
CRAL-TRIO protein family. Biochemistry 42:6467–6474
16. Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M,
Simons B, Chang P, di Sant’agnese A, Messing EM, Yeh S
(2005) Tocopherol-associated protein suppresses prostate cancer
cell growth by inhibition of the phosphoinositide 3-kinase path-
way. Cancer Res 65:9807–9816
17. Wen XQ, Li XJ, Su ZL, Liu Y, Zhou XF, Cai YB, Huang WT,
Gao X (2007) Reduced expression of alpha-tocopherol-associated
protein is associated with tumor cell proliferation and the
increased risk of prostate cancer recurrence. Asian J Androl
9:206–212
18. Zingg JM, Ricciarelli R, Andorno E, Azzi A (2002) Novel 5’
exon of scavenger receptor CD36 is expressed in cultured human
Mol Biol Rep (2010) 37:3503–3508 3507
123
vascular smooth muscle cells and atherosclerotic plaques. Arte-
rioscler Thromb Vasc Biol 22:412–417
19. Shibata N, Arita M, Misaki Y, Dohmae N, Takio K, Ono T, Inoue
K, Arai H (2001) Supernatant protein factor, which stimulates the
conversion of squalene to lanosterol, is a cytosolic squalene
transfer protein and enhances cholesterol biosynthesis. Proc Natl
Acad Sci USA 98:2244–2249
20. Mokashi V, Singh DK, Porter TD (2005) Supernatant protein
factor stimulates HMG-CoA reductase in cell culture and in vitro.
Arch Biochem Biophys 433:474–480
21. Shibata N, Jishage K, Arita M, Watanabe M, Kawase Y, Nis-
hikawa K, Natori Y, Inoue H, Shimano H, Yamada N, Tsujimoto
M, Arai H (2006) Regulation of hepatic cholesterol synthesis by a
novel protein (SPF) that accelerates cholesterol biosynthesis.
Faseb J 20:2642–2644
22. Yamauchi J, Iwamoto T, Kida S, Masushige S, Yamada K, Esashi
T (2001) Tocopherol-associated protein is a ligand-dependent
transcriptional activator. Biochem Biophys Res Commun
285:295–299
23. Funaba M, Murakami M, Ikeda T, Ogawa K, Tsuchida K, Sugino
H (2006) Identification of tocopherol-associated protein as an
activin/TGF-beta-inducible gene in mast cells. Biochim Biophys
Acta 1763:900–906
24. Shan L, Kawakami T, Asano S, Noritake S, Yoshimoto D, Ya-
mashita K, Kikkawa H, Kinoshita M, Matsubara S (2009) Inverse
relationship between Sec14l3 mRNA/protein expression and
allergic airway inflammation. Eur J Pharmacol 616(1–3):293–300
25. Johnykutty S, Tang P, Zhao H, Hicks DG, Yeh S, Wang X (2009)
Dual expression of alpha-tocopherol-associated protein and
estrogen receptor in normal/benign human breast luminal cells
and the downregulation of alpha-tocopherol-associated protein in
estrogen-receptor-positive breast carcinomas. Mod Pathol
22(6):770–775
26. Neuzil J, Dong LF, Wang XF, Zingg JM (2006) Tocopherol-
associated protein-1 accelerates apoptosis induced by alpha-
tocopheryl succinate in mesothelioma cells. Biochem Biophys Res
Commun 343:1113–1117
27. Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA,
Yeager M, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2009)
Association of variants in two vitamin e transport genes with
circulating vitamin e concentrations and prostate cancer risk.
Cancer Res 69(4):1429–1438
28. Zingg JM, Azzi A (2009) Comment re: Vitamin E transport gene
variants and prostate cancer. Cancer Res 69(16):6756; author
reply 6756
29. Wang X, Ni J, Hsu CL, Johnykutty S, Tang P, Ho YS, Lee CH,
Yeh S (2009) Reduced expression of tocopherol-associated pro-
tein (TAP/Sec14L2) in human breast cancer. Cancer Investig
27(10):971–977
30. Schaaf G, Ortlund EA, Tyeryar KR, Mousley CJ, Ile KE, Garrett
TA, Ren J, Woolls MJ, Raetz CR, Redinbo MR, Bankaitis VA
(2008) Functional anatomy of phospholipid binding and regula-
tion of phosphoinositide homeostasis by proteins of the sec14
superfamily. Mol Cell 29(2):191–206
31. Curwin AJ, Fairn GD, McMaster CR (2009) Phospholipid
transfer protein Sec14 is required for trafficking from endosomes
and regulates distinct trans-Golgi export pathways. J Biol Chem
284(11):7364–7375
32. Schaaf G, Betts L, Garrett TA, Raetz CR, Bankaitis VA (2006)
Crystallization and preliminary X-ray diffraction analysis of
phospholipid-bound Sfh1p, a member of the Saccharomyces ce-
revisiae Sec14p-like phosphatidylinositol transfer protein family.
Acta Crystallogr Sect F Struct Biol Cryst Commun 62:1156–1160
33. Zingg JM, Azzi A, Meydani M (2008) Genetic polymorphisms as
determinants for disease-preventive effects of vitamin E. Nutr
Rev 66(7):406–414
34. Gao K, Masuda A, Matsuura T, Ohno K (2008) Human branch
point consensus sequence is yUnAy. Nucleic Acids Res
36(7):2257–2267
3508 Mol Biol Rep (2010) 37:3503–3508
123
